ADIPOQ and IL6 variants are associated with a pro-inflammatory status in obeses with cardiometabolic dysfunction

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author OLIVEIRA, Raquel de
MORAES, Tamiris Invencioni
CERDA, Alvaro
HIRATA, Mario Hiroyuki
FAJARDO, Cristina Moreno
SOUSA, Marcela Correia
DOREA, Egidio Lima FMUSP-HC
BERNIK, Myrcia Martins Silveira
HIRATA, Rosario Dominguez Crespo
dc.date.issued 2015
dc.identifier.citation DIABETOLOGY & METABOLIC SYNDROME, v.7, article ID 34, 9p, 2015
dc.identifier.issn 1758-5996
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/10048
dc.description.abstract Background: Polymorphisms in genes encoding adiponectin (ADIPOQ) and interleukin-6 (IL6) have been associated with adiposity and obese-related phenotypes. This study investigated the relationship of ADIPOQ and IL6 gene polymorphisms with pro-inflammatory and cardiometabolic markers in obese patients. Methods: Anthropometric and body composition parameters were measured in 249 Brazilian subjects (30 to 68 yr). Metabolic and inflammatory markers and adipokines were analyzed in blood samples. ADIPOQ rs2241766 (45 T > G) and IL6 rs1800795 (-174G > C) polymorphisms were analyzed by real-time PCR and PCR-RFLP, respectively. Results: Type 2 diabetes, hypertension, dyslipidemia and increased values of waist circumference, body fat, leptin, fibrinogen, IL-1 beta, hsCRP and TNF alpha were related to obesity (p < 0.05). Multiple linear regression analysis showed a positive correlation between BMI and waist circumference, body fat, leptin, fibrinogen, PAI-1, IL-1 beta, hsCRP and TNF alpha values (p < 0.001) but not with adiponectin. Obese group had altered metabolic status, resistance to leptin and insulin, and atherogenic and pro-inflammatory profiles. ADIPOQ and IL6 variants were not directely related to obesity, leptin resistance or alterations in cardiometabolic markers. Individuals carrying ADIPOQ 45G allele (TG + GG genotype) had higher IL-6, IL-1 beta and TNF alpha levels than TT genotype carriers (p < 0.05). IL6 -174GG genotype was associated with increased IL-1 beta levels (p = 0.033). Conclusion: Obesity is associated with leptin resistance, cardiometabolic alterations and a pro-inflammatory status. Our results are suggestive that ADIPOQ and IL6 polymorphisms contribute to cardiometabolic risk in obese individuals.
dc.description.sponsorship · Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) (Brazil) [2009/10069-2]
· FAPESP
· Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
· Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) (Brazil)
· CAPES
· Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT) (Chile)
dc.language.iso eng
dc.publisher BIOMED CENTRAL LTD
dc.relation.ispartof Diabetology & Metabolic Syndrome
dc.rights openAccess
dc.subject Obesity; Inflammation; Adiponectin; Interleukin-6; Gene polymorphism
dc.subject.other serum adiponectin concentrations; insulin-resistance; cardiovascular-disease; mexican adolescents; gene polymorphisms; energy-balance; body-weight; fat mass; obesity; interleukin-6
dc.title ADIPOQ and IL6 variants are associated with a pro-inflammatory status in obeses with cardiometabolic dysfunction
dc.type article
dc.rights.holder Copyright BIOMED CENTRAL LTD
dc.identifier.doi 10.1186/s13098-015-0027-2
dc.identifier.pmid 25897330
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author DOREA, Egidio Lima:HU:DVCLME-62
hcfmusp.author.external · OLIVEIRA, Raquel de:Univ Sao Paulo, Sch Pharmaceut Sci, BR-05508900 Sao Paulo, SP, Brazil
· MORAES, Tamiris Invencioni:Univ Sao Paulo, Sch Pharmaceut Sci, BR-05508900 Sao Paulo, SP, Brazil
· CERDA, Alvaro:Univ Sao Paulo, Sch Pharmaceut Sci, BR-05508900 Sao Paulo, SP, Brazil; Univ La Frontera, BIOREN CEGIN, Ctr Mol Biol & Pharmacogenet, Temuco, Chile
· HIRATA, Mario Hiroyuki:Univ Sao Paulo, Sch Pharmaceut Sci, BR-05508900 Sao Paulo, SP, Brazil
· FAJARDO, Cristina Moreno:Univ Sao Paulo, Sch Pharmaceut Sci, BR-05508900 Sao Paulo, SP, Brazil
· SOUSA, Marcela Correia:Univ Sao Paulo, Sch Pharmaceut Sci, BR-05508900 Sao Paulo, SP, Brazil
· BERNIK, Myrcia Martins Silveira:Univ Sao Paulo, Univ Hosp, BR-05508900 Sao Paulo, SP, Brazil
· HIRATA, Rosario Dominguez Crespo:Univ Sao Paulo, Sch Pharmaceut Sci, BR-05508900 Sao Paulo, SP, Brazil
hcfmusp.origem.id 2-s2.0-84928037911
hcfmusp.origem.id WOS:000353188700001
hcfmusp.publisher.city LONDON
hcfmusp.publisher.country ENGLAND
hcfmusp.relation.reference · Al-Daghri NM, 2012, GENE, V493, P142, DOI 10.1016/j.gene.2011.11.045
· Antonopoulos AS, 2013, INT J CARDIOL, V168, P326, DOI 10.1016/j.ijcard.2012.09.053
· Bastien M, 2014, PROG CARDIOVASC DIS, V56, P369, DOI 10.1016/j.pcad.2013.10.016
· Blüher Matthias, 2012, Diabetes Metab J, V36, P317, DOI 10.4093/dmj.2012.36.5.317
· Bouhaha R, 2010, CLIN BIOCHEM, V43, P549, DOI 10.1016/j.clinbiochem.2010.01.008
· Bray GA, 2006, J MED CHEM, V49, P4001, DOI 10.1021/jm0680124
· Cardellini M, 2005, DIABETES CARE, V28, P2007, DOI 10.2337/diacare.28.8.2007
· Cohen SS, 2011, OBESITY, V19, P2053, DOI 10.1038/oby.2010.346
· Di Renzo L, 2008, CURR PHARM DESIGN, V14, P2699, DOI 10.2174/138161208786264061
· Finucane MM, 2011, LANCET, V377, P557, DOI 10.1016/S0140-6736(10)62037-5
· Goyenechea E, 2007, METABOLISM, V56, P1643, DOI 10.1016/j.metabol.2007.07.005
· Gupta A, 2011, HUM EXP TOXICOL, V30, P1445, DOI 10.1177/0960327110393763
· Guzman-Ornelas Milton-Omar, 2012, Diabetes Metab Syndr Obes, V5, P369, DOI 10.2147/DMSO.S35434
· Hoene M, 2008, OBES REV, V9, P20, DOI 10.1111/j.1467-789X.2007.00410.x
· Kahn SE, 2006, NATURE, V444, P840, DOI 10.1038/nature05482
· Li LL, 2007, CLIN EXP PHARMACOL P, V34, P1287, DOI 10.1111/j.1440-1681.2007.04713.x
· Martin SS, 2008, J AM COLL CARDIOL, V52, P1201, DOI 10.1016/j.jacc.2008.05.060
· Mendoza-Carrera F, 2010, ARCH MED RES, V41, P472, DOI 10.1016/j.arcmed.2010.08.015
· Moleres A, 2009, J PHYSIOL BIOCHEM, V65, P405, DOI 10.1007/BF03185936
· Moleres A, 2012, J PEDIATR-US, V161, P466, DOI 10.1016/j.jpeds.2012.04.004
· Mousavinasab F, 2006, MOL GENET METAB, V87, P147, DOI 10.1016/j.ymgme.2005.08.010
· Oliveira CSV, 2012, J DIABETES COMPLICAT, V26, P94, DOI 10.1016/j.jdiacomp.2012.02.008
· Park JW, 2011, EPIDEMIOL HLTH, V33
· Popko K, 2010, EUR J MED RES, V15, P123
· Pyrzak B, 2009, Eur J Med Res, V14 Suppl 4, P196
· Qi L, 2007, J CLIN ENDOCR METAB, V92, P3618, DOI 10.1210/jc.2007-0877
· Ramirez-Lopez G, 2013, ARCH MED RES, V44, P62, DOI 10.1016/j.arcmed.2012.10.019
· Rizk NM, 2013, ANGIOLOGY, V64, P257, DOI 10.1177/0003319712455497
· Knight ZA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011376
· Siitonen N, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-5
· SONE Y, 2010, J NUTR SCI VITAMINOL, V56, P123
· Strandberg L, 2008, OBESITY, V16, P710, DOI 10.1038/oby.2007.95
· Tabatabaei-Malazy Ozra, 2010, Rev Diabet Stud, V7, P241, DOI 10.1900/RDS.2010.7.241
· Turer AT, 2012, DIABETOLOGIA, V55, P2319, DOI 10.1007/s00125-012-2598-x
· Vde O. Leal, 2013, CLIN CHIM ACTA, V419, P87
· Wassel CL, 2010, OBESITY, V18, P2333, DOI 10.1038/oby.2010.85
· Wu JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095270
· Yoo Hye Jin, 2014, World J Diabetes, V5, P357, DOI 10.4239/wjd.v5.i3.357
· Yu ZB, 2012, OBESITY, V20, P396, DOI 10.1038/oby.2011.148
dc.description.index PubMed
hcfmusp.citation.scopus 2
hcfmusp.citation.wos 2
hcfmusp.affiliation.country Brasil
hcfmusp.affiliation.country Chile


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics